{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination ","description":"Interviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief  Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data  on the relevance of KRAS tumor status&amp;mdash;i.e., whether the gene is wild-type or  mutant determines the sensitivity of the tumor to anti-EGF or anti-VEGF receptor  therapy. He also discusses the disappointing finding that blocking both of these  proliferation pathways does not lead to improved efficacy when two targeted  drugs are used in combination.","author_name":"OT Broadcast News","author_url":"http:\/\/www.oncology-times.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/1110451\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/1110451"}